businessdev - splash

We can offer out-licensing opportunities of our proprietary technologies and/or vaccine programmes and we search for innovative technologies supplementing our in-house technologies and programmes

BUSINESS DEVELOPMENT

Bavarian Nordic owns a broadly applicable MVA-BN® vaccine platform technology, which can be applied to develop multiple vaccines across various disease areas, tested in more than 3,400 persons.

We can offer out-licensing opportunities of our proprietary technologies and/or vaccine programmes and we search for innovative technologies supplementing our in-house technologies and programmes.

We are also interested in research collaborations with academic groups and biotech companies. We might be able to provide technologies and production know-how that your organization can use to explore scientific arenas that lay beyond your available resources and skills. 

Meet us

ASCO Annual Meeting

June 1-5, 2012
Chicago, USA
http://chicago2012.asco.org/

2012 BIO International Convention

June 18-21, 2012
Boston, USA
convention.bio.org

European Pharma Licensing Symposium

September 17-19, 2012
Budapest, Hungary